tacrine has been researched along with vorinostat in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 2 (40.00) | 2.80 |
Authors | Studies |
---|---|
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Bolognesi, ML; da Costa Nunes, JL; de Oliveira Miranda, C; de Oliveira, AS; Gandini, A; Gervasoni, S; Jung, M; Kobrlova, T; Massenzio, F; Monti, B; Petralla, S; Rossi, M; Senger, J; Simões Heyn Roth Cardoso, G; Soares Romeiro, LA; Soukup, O; Vistoli, G | 1 |
Andrisano, V; De Simone, A; Milelli, A; Tumiatti, V | 1 |
Bian, Y; Chen, Y; Li, Y; Pei, Y; Ren, W; Sang, S; Sun, H | 1 |
1 review(s) available for tacrine and vorinostat
Article | Year |
---|---|
Inhibition of Histone Deacetylase 6 (HDAC6) as a therapeutic strategy for Alzheimer's disease: A review (2010-2020).
Topics: Acetamides; Alzheimer Disease; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Models, Molecular; Molecular Structure; Neuroprotective Agents | 2021 |
4 other study(ies) available for tacrine and vorinostat
Article | Year |
---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Novel Sustainable-by-Design HDAC Inhibitors for the Treatment of Alzheimer's Disease.
Topics: | 2019 |
Glycogen Synthase Kinase 3β: A New Gold Rush in Anti-Alzheimer's Disease Multitarget Drug Discovery?
Topics: Alzheimer Disease; Drug Discovery; Glycogen Synthase Kinase 3 beta; Humans; Phosphorylation | 2021 |